SOLICITATION NOTICE
A -- Neutralizing Monoclonal Antibodies for Type A Botulinum Neurotoxins
- Notice Date
- 9/20/2004
- Notice Type
- Solicitation Notice
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Contract Management Program 6700 B Rockledge Room 3214 MSC7612, Bethesda, MD, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- NIH-NIAID-DMID-PR2004-01
- Response Due
- 11/5/2004
- Archive Date
- 11/20/2004
- Description
- This notice is a combined synopsis/solicitation for other than commercial items. This announcement constitutes the only solicitation; offers are being requested and a written solicitation will not be issued. This procurement is being conducted under the Simplified Acquisition Procedures (SAP) set forth in FAR Part 13. This notice is being issued as a Request for Proposal (RFP) to develop and manufacture human or human compatible monoclonal antibodies (mAbs) for evaluation in preclinical and clinical studies as therapies for botulism. Monoclonal Abs proposed by the offeror for development under this RFP should have demonstrated potency in a standardized mouse protection bioassay for botulinum neurotoxins serotypes A1 and A2. The Project BioShield Act of 2004, enacted on July 21, 2004, authorizes the Secretary, Department of Health and Human Services (DHHS), through the program carried out by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), to simplify and expedite the award of contracts to perform or support research and development of countermeasures determined by the Secretary to be a priority to treat, identify, or prevent harm from any biological, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security, or adverse health consequences that may arise from using such a countermeasure. Consistent with this new authority, NIAID is announcing this simplified acquisition. The growing terrorist threat of radiological or nuclear attack includes a range of possibilities beyond those historically envisioned. In addition to detonation of a nuclear bomb, the civilian population may be at risk from radiological dispersion devices such as dirty bombs that utilize discarded nuclear materials, as well as attacks upon nuclear reactor facilities. No medical countermeasures and detection program currently exist within a federal civilian research institution to address these needs. The urgent, general need for medical countermeasures and detection methods against radiation injury, and the particular need for methods to reliably prevent immune functions after exposure, underlie the creation of this targeted initiative.
- Record
- SN00677350-W 20040922/040920234848 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |